RU2012120834A - Фармацевтические композиции для стимулирования стволовых клеток - Google Patents

Фармацевтические композиции для стимулирования стволовых клеток Download PDF

Info

Publication number
RU2012120834A
RU2012120834A RU2012120834/15A RU2012120834A RU2012120834A RU 2012120834 A RU2012120834 A RU 2012120834A RU 2012120834/15 A RU2012120834/15 A RU 2012120834/15A RU 2012120834 A RU2012120834 A RU 2012120834A RU 2012120834 A RU2012120834 A RU 2012120834A
Authority
RU
Russia
Prior art keywords
growth factor
pharmaceutical composition
fgf
bmp
factor
Prior art date
Application number
RU2012120834/15A
Other languages
English (en)
Russian (ru)
Inventor
Роланд ГОРДОН-БЕРЕСФОРД
Винциан ГОССИН
ДВАНЬИСА Жан-Пьер ЛАТЕР
Кристиан ОМСИ
Original Assignee
Кардиоз Биосайнсиз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кардиоз Биосайнсиз С.А. filed Critical Кардиоз Биосайнсиз С.А.
Publication of RU2012120834A publication Critical patent/RU2012120834A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2012120834/15A 2009-12-02 2010-12-02 Фармацевтические композиции для стимулирования стволовых клеток RU2012120834A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2009066251 2009-12-02
EPPCT/EP2009/066251 2009-12-02
PCT/EP2010/068700 WO2011067317A1 (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.

Publications (1)

Publication Number Publication Date
RU2012120834A true RU2012120834A (ru) 2014-01-20

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012120834/15A RU2012120834A (ru) 2009-12-02 2010-12-02 Фармацевтические композиции для стимулирования стволовых клеток

Country Status (12)

Country Link
JP (1) JP2013512877A (enExample)
KR (1) KR20120099751A (enExample)
CN (1) CN102711798A (enExample)
AU (1) AU2010326633A1 (enExample)
BR (1) BR112012013164A2 (enExample)
CA (1) CA2781493A1 (enExample)
IL (1) IL219901A0 (enExample)
MX (1) MX2012005976A (enExample)
NZ (1) NZ599930A (enExample)
RU (1) RU2012120834A (enExample)
TW (1) TW201141510A (enExample)
WO (1) WO2011067317A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000699A1 (en) * 2014-07-07 2016-01-07 Medipost Co., Ltd. Hair growth promoting capacity of conditioned media of stimulated stem cells and use thereof
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
KR102106710B1 (ko) 2018-10-11 2020-05-04 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
WO2021187895A1 (ko) * 2020-03-17 2021-09-23 주식회사 히에라바이오 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
KR20240131080A (ko) * 2023-02-23 2024-08-30 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法
KR102990665B1 (ko) * 2024-09-19 2026-07-15 부산대학교 산학협력단 Ccl5를 포함하는 골수 유래 줄기세포의 활성화 촉진용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
EP2236153A3 (en) * 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Compositons and methods for treating cardiac conditions
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Also Published As

Publication number Publication date
IL219901A0 (en) 2012-07-31
JP2013512877A (ja) 2013-04-18
TW201141510A (en) 2011-12-01
AU2010326633A1 (en) 2012-05-31
KR20120099751A (ko) 2012-09-11
MX2012005976A (es) 2012-06-25
BR112012013164A2 (pt) 2016-03-01
CA2781493A1 (en) 2011-06-09
WO2011067317A1 (en) 2011-06-09
NZ599930A (en) 2014-04-30
CN102711798A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
JP2013512877A5 (enExample)
US20120301538A1 (en) Pharmaceutical compositions for the stimulation of stem cells
KR20120099751A (ko) 줄기 세포 자극용 약학 조성물
Kawamoto et al. Nerve growth factor and wound healing
Ensoli et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.
Hughes et al. Members of several gene families influence survival of rat motoneurons in vitro and in vivo
Ten Dijke et al. Growth factors for wound healing
Schultz et al. Neovascular growth factors
RU2007146986A (ru) Способы лечения опухолей головного мозга с использованием антител
DE69626034T2 (de) Zusammensetzung für verbesserung der pankreasfunktion
WO1994003199A1 (en) Method of enhancing differentiation and survival of neuronal precursor cells
US5962459A (en) Therapeutic active agent for treatment of neuron degenerative diseases
Westermann et al. Basic fibroblast growth factor (bFGF), a multifunctional growth factor for neuroectodermal cells
CN101549148A (zh) 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用
Unsicker Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives
WO2002094872A1 (en) Therapeutic uses of keratinocyte growth factor-2
AU2001258322B2 (en) Formulation having mobilising activity
AU2001258322A1 (en) Formulation having mobilising activity
Finklestein et al. Increased levels of basic fibroblast growth factor (bFGF) following focal brain injury
de Haan et al. Prophylactic pretreatment of mice with hematopoietic growth factors induces expansion of primitive cell compartments and results in protection against 5-fluorouracil-induced toxicity
Tatter et al. Neurotrophic factor protection against excitotoxic neuronal death
Aloisi Growth factors
Zhang et al. Osteogenic potential of icariin compared with recombinant human bone morphogenetic protein 2 in vitro: A preliminary study
Hefti et al. Neurotrophic factors and neurodegenerative diseases
Knöchel et al. Mesoderm induction and blood island formation by angiogenic growth factors and embryonic inducing factors

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150625